Collegium Pharmaceutical Inc

NASDAQ:COLLUnited States

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

Contact Information

Headquarters

100 Technology Center DrSTOUGHTON, MA, United States 02072-4710

Phone

781-713-3699

Fax

---

Executives

Chairman of the Board

Michael Heffernan

President, Chief Executive Officer, Director

Vikram Karnani

Chief Financial Officer, Executive Vice President

Colleen Tupper

Executive Vice President, Chief Administrative Officer, General Counsel, Secretary

Shirley Kuhlmann

Executive Vice President, Chief Commercial Officer

Scott Dreyer